We present the Brain-Age Score (BAS) as a magnetic resonance imaging (MRI)-based index for Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Selecting a set of relevant markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has become a challenging task given the wealth of regional pathologic information that can be extracted from multimodal imaging data. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Higher teacher‐student ratio was associated with greater gray matter volume (β = 6.25, 95% CI: 1.57, 10.92) but was not associated hippocampal volume (β = ‐0.01, 95% CI: ‐0.14, 0.11), ventricular volume (β = ‐0.04, 95% CI: ‐0.13, 0.04), or white matter hyperintensity (β = ‐0.02, 95% CI: ‐0.31, 0.26) (Table 2). 5 key findings →
Participants: 450 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 5757 participants (21.7% Black, 20.3% Latinx, 58.1% AORE), we found lower odds of amyloid positivity in Black (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.62-0.83) and Latinx (OR: 0.78, 95% CI: 0.67-0.91) compared to AORE. 4 key findings →
Participants: 5,757 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Average age of participants was 66 (21-88) years. 25 were biologically female and 15 were amyloid positive. 5 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In both cohorts there were significant associations between CSF MTBR-tau243 and the temporal meta-ROI (BioFINDER-2: t = 17.1, p < 0.001, Knight-ADRC: t=11.0, p <0.001). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
41/100
A total of 51 patients with AD, age (median: 73 years) and 53 cognitively normal subjects (median age: 69) were included. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) represents a heterogeneous state between normal aging and dementia, with varied transition pathways. 3 key findings →
Participants: 272 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• This analysis consists of 567 participants revealed that vitamin B12 deficiency, not folate or vitamin B1 deficiency was associated with hippocampal atrophy detected by MRI-VSRAD analysis. • Vitamin B12 deficiency was associated with hyperhomocysteinemia. • Clear correlations were observed between hippocampal atrophy and vitamin B12 value. 4 key findings →
Participants: 323 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
41/100
IRMA can be used to learn and disregard center-specific information in features extracted from brain $$^{18}$$ 18 F-FDG PET scans, while retaining disease-specific information. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MAP-RTAP (AUC = 0.78) and pTau/Aβ42 (AUC = 0.76) were the best performing individual biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study highlights the potential of integrating 18 F-FDG-PET with CSF biomarkers to improve the diagnosis, prognosis, and monitoring of AD, emphasizing the complexity and regional specificity of biomarker interactions in neurodegeneration. 1 key finding →
Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors. 5 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 156 patients were clinically diagnosed with dementia based on the 2011 NIA-AA criteria, regardless of specific disease etiology, and all exhibited significant brain atrophy on anatomical magnetic resonance imaging (MRI), indicating neuronal injury (N+). 5 key findings →
Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study, we present a comprehensive pipeline to train and compare a broad spectrum of machine learning and deep learning brain clocks, integrating diverse preprocessing strategies and correction terms. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
86.8% of patients in this cohort presented more than one pathology. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results suggest that microglial activation is a major phenomenon linking Aβ and astrocyte reactivity in the living AD brain. 5 key findings →
Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
All participants had heterozygous c.1184A > G, p.Asp395Gly in VCP. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• Anterior cingulate cortex (ACC) hypometabolism is a non-specific finding in many brain disorders. • ACC hypometabolism was more common in vascular cognitive impairment and dementia (VCID) than Alzheimer dementia (AD). • ACC hypometabolism correlated with cerebral small vessel disease markers. • ACC hypometabolism may be associated with motor stereotypies in VCID. • FDG-PET patterns of hypometabolism may identify vascular contributions to cognitive impairment The anterior cingulate cortex (ACC) is an important hub in the executive and salience networks. 2 key findings →
Participants: 379 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Individual biomarkers significantly predict decline across multiple cognitive domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma Aβ levels and regional WMH burden are associated with glymphatic dysfunction as indicated by reduced ALPS. 3 key findings →
Participants: 216 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results of the present study suggest that increased 18 F-THK5351 uptake might be a useful predictor of poor prognosis among Aβ- aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498). 3 key findings →
Design: clinical trial Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mechanisms underlying blood-brain barrier (BBB) compromise in human immunodeficiency virus (HIV) infection and the ways in which BBB compromise might impair neurocognitive function remain poorly understood. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From across this tag
10 of the 2,885 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Subtracting First Principal Component May Improve 4R Tau Detectability on [ 18 F]Flortaucipir Tau PET
- The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study
- Sex differences in the progression of glucose metabolism dysfunction in Alzheimer's disease
- Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease
- Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis
- Association Between Plasma Metabolomic Profile and Machine Learning‐Based Brain Age
- Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
- Brain atrophy in type 2 diabetes: regional distribution and influence on cognition
- Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease
- Stress predicts brain changes in children: a pilot longitudinal study on youth stress, posttraumatic stress disorder, and the hippocampus
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →